Hani Nur

HA TECH is an Australian based Company, Developing & Delivering innovative Diagnostic and Pharmaceuticals products, focuses on the diagnosis of serious infectious diseases: respiratory Including COVID-19, sexually transmitted infection (STI) and mosquito-borne diseases that affect hundreds of millions of people worldwide and are among the most urgent global health challenges. The Company is making long-term investments to develop pharmaceutical products and Active Ingredients to treat top chronic diseases such as Cardiovascular and diabetes which are major health problem in Australia and globally. The Company has a diagnostic manufacturing facility at Norwest Business Park, Sydney, Australia; also recently has invested in Bangladesh to set up It's Bulk API (Active Pharmaceutical Ingredient) and diagnostic raw materials production facilities. Key Projects and Product Pipeline: - The Company has launched a multi-gene target SARS-CoV-2 RT-PCR kit in October 2020 that is one of the fastest available globally. The Kit has received TGA approval in December 2020 and available for sale is Australia and overseas. The company is also developing a range of other diagnostic kits concurrently such as a multiplex kit for testing SARS-CoV-2, Influenza and other respiratory viruses and a kit for differentiating Dengue, Chikungunya and Zika virus. Development has also begun for a rapid SARS-CoV-2 point of care test and an environmental SARS-CoV-2 test kit. - The development and manufacturing of Biotherapeutic drugs; and Active Pharmaceuticals Ingredients (APIs) for the Cardiovascular, Antidiabetic, Anti-Ulcerant and Oncology applications; - The development & commercialization of novel technologies based on smart materials such as polymer nanoparticles, polymer hydrogel and hydrogel membranes for specific medical applications.

Memphasys Ltd (ASX: MEM) is an Australian publicly listed Bio-technology company that develops/ commercialises innovative separation techniques based on membrane technology. The company was formerly known as ‘NuSep Ltd’ and ‘Gardipore Ltd before that, also sold precast electrophoresis gels. THE KEY PROJECTS THAT WERE DIRECTLY MANAGED: •Long life poly-acrylamide electrophoresis Pre-cast gels (2010-12) The development of the long shelf-life gel product was company’s one of the key objectives to compete with the major competitor companies: Invitrogen, Bio-Rad. The new gel formulation was invented within six months; the new product was sold globally as NG, NB and NN series of NuSep’s long life gels. A patent was filed on the invention. The gel business was sold to Dycent Biotech (Shanghai). • Poly-acrylamide membranes for Blood Plasma Fractionation application (2012-15). Continuous improvement made in the membrane formulation (with different pore size to separate valuable proteins from blood plasma based on it's size and charge), the manufacturing process and QC to meet the requirements for the company’s PrIME (preparative isolation by membrane electrophoresis) project. Besides the development work, managed adequate production and supply of the membranes to PrIME until PrIME spun-out as a separate company PrIME BIOLOGICS based in Singapore. A patent was filed on the invention. •Novel bio-compatible membrane development for Fertility Medical Device (2016- Feb 2019). The project objective was to develop a biocompatible polymer hydrogel membrane by replacing the toxic monomer ‘acrylamide’ that was used to manufacture the existing membrane used for the sperm separation device. The project was successfully completed with the Chemical Engineering department of the University of Melbourne by replacing the toxic monomer without affecting the membrane functionality. Two patents were filed on the inventions.

The research involved the manufacture and characterisation of polymeric thin films and studying the uptake and release of active materials/fragrance from the prepared films to be used in the delivery of active materials or fragrance via an oral route.